Promising Test for Dendreon's Prostate Cancer Drug

New York Times by Andrew Pollack | Apr. 14, 2009 (Special Report)

A prostate cancer drug developed by the Seattle biotechnology company Dendreon prolonged the lives of men in a decisive clinical trial, the company announced Tuesday morning.

The widely anticipated results could pave the way for the drug, called Provenge, to become the first so-called therapeutic cancer “vaccine” to win approval in the United States after numerous failures of such drugs.

“This looks like a proof of concept that ... Full Story »

Posted by Christina Wootton

See All Reviews »

View

Review

Christina Wootton
3.8
 by Christina Wootton - Apr. 14, 2009

This piece is a presentation of the groundbreaking prostate cancer drug that has the potential to greatly benefit the vast majority of those individuals suffering from prostate cancer. The well-written publication gives numbers, quotes, and support for providing knowledge regarding this topic to the general public. It offers scientific evidence and explanation to how the drug works, giving the story a contextual basis for its newsworthy topic.

Christina posted this story.

See All Reviews »

Christina's Rating

Overall
3.8

Good
from 11 answers
Quality
3.9
Facts
4.0
Fairness
4.0
Sourcing
3.0
Style
4.0
Context
4.0
Depth
5.0
Enterprise
4.0
Relevance
3.0
Popularity
3.5
Recommendation
3.0
Credibility
4.0
More How our ratings work »